Charleston Aesthetics had provided Qwo services for years without issue; however, in light of the recent announcement by the manufacturer Endo, we will no longer be carrying or injecting this product. Despite not having any poor health outcomes leading to this announcement, we are opting to discontinue Qwo out of an abundance of caution for our clients. If you have received Qwo injections from us in the past and have questions or concerns about this announcement or our decision, we invite you to call us at 843-762-9014. The official announcement from Endo regarding the discontinuation of the product is below.

​

​

Endo International plc (OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

​

For more than a year, Endo worked to address those concerns, including launching an open-label study in June 2022, APHRODITE, to test different interventions and whether they might mitigate bruising. Although certain APHRODITE study cohorts' results reflected a modest reduction of bruising area and severity, none achieved a consistent level of reduced bruising following initial treatment to adequately alleviate the market's concerns.

​

"After careful consideration, we have determined that QWO does not represent a viable commercial opportunity for Endo," said Blaise Coleman, President and CEO of Endo. "This difficult decision unfortunately results in a workforce reduction. We are grateful for the dedication and hard work of all team members who supported QWO and our Endo Aesthetics business, and we are committed to providing support and assistance to our impacted team members."

QWO remains an FDA-approved product with clinically proven results and an established safety profile.

​

Review the full press release here.